Phase i trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies

Amit Mahipal, Dave Shibata, Erin Siegel, Gregory Springett, Khaldoun Almhanna, William Fulp, Irene Williams-Elson, Richard Kim

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Summary: Introduction Pasireotide (SOM230) is a somatostatin analog with high binding affinity for somatostatin receptors including sst1, 2, 3 and 5 and inhibit insulin like growth factor-1. Blocking of IGF-1 receptor (IGF-1R) in combination with cytotoxic chemotherapy has demonstrated additive or synergistic activity in pre-clinical models. This study aimed to evaluate the maximum tolerated dose (MTD) of pasireotide in combination with standard FOLFIRI (5-fluorouracil, leucovorin and irinotecan) regimen in patients with gastrointestinal malignancies. Methods This was a phase 1, 3∈+∈3 design, open-label dose escalation study conducted in sequential cohorts to determine the MTD of pasireotide in combination with FOLFIRI. All patients had gastrointestinal malignancies and were previously treated. Sixteen patients enrolled in five dose cohorts at pasireotide doses of 40, 60, 80, 100 and 120 mg were evaluated for safety and tolerability of the combination. Results The tumor types of the enrolled subjects included esophageal (n∈=∈5), biliary tract (n∈=∈3), colon (n∈=∈3), gastric (n∈=∈2), pancreatic (n∈=∈1), anal (n∈=∈1) and small bowel (n∈=∈1). No dose limiting toxicities were observed. The most common adverse events related to the study treatment included hyperglycemia (81 %), neutropenia (62 %), thrombocytopenia (44 %), anorexia (44 %), dehydration (25 %) and elevated alkaline phosphatase (25 %). Two patients had partial response and 7 patients had stable disease. Plasma levels of IGF-1 and IGFBP-3 were significantly reduced after treatment with pasireotide. Discussion Combination of pasireotide and FOLFIRI has manageable safety profile and is feasible in patients with gastrointestinal malignancies. Preliminary signals of activity were observed. Larger phase II trials are warranted.

Original languageEnglish (US)
Pages (from-to)1093-1099
Number of pages7
JournalInvestigational New Drugs
Volume33
Issue number5
DOIs
StatePublished - Oct 22 2015
Externally publishedYes

Keywords

  • Chemotherapy
  • Gastrointestinal cancers
  • Irinotecan
  • SOM230

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase i trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies'. Together they form a unique fingerprint.

Cite this